Material Rejection and Re-issuance
Material rejection and re-issuance is a process used to manage the disposition of materials that have been identified as non-conforming or unsuitable for their intended use. The purpose of this process is to ensure that materials that do not meet the required specifications or quality standards are removed from use and properly disposed of, while ensuring that suitable replacement materials are made available as needed.
The steps involved in
material rejection and re-issuance typically include the following:
1.
Identification: Materials that do not meet the required
specifications or quality standards are identified through inspections,
testing, or other means.
2.
Quarantine: The identified materials are placed in
quarantine to prevent them from being used or shipped.
3.
Evaluation: The non-conforming materials are evaluated to
determine the root cause of the issue and to identify any potential risks
associated with the use of these materials.
4.
Disposition: Based on the evaluation, the non-conforming
materials are either rejected, reworked, or scrapped.
5.
Documentation: All actions taken during the material
rejection and re-issuance process are documented, including the reason for the
rejection, the disposition of the material, and any actions taken to prevent a
similar issue in the future.
6.
Re-issuance: If replacement materials are needed, suitable
materials are identified, evaluated, and issued for use.
Material rejection and
re-issuance is an important process for ensuring that materials used in the
production of pharmaceuticals are of the required quality and meet the
necessary specifications. This helps to ensure that products are safe and
effective, and that they meet the requirements of regulatory agencies and
industry standards.
Comments
Post a Comment